CL2012003185A1 - Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica. - Google Patents

Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica.

Info

Publication number
CL2012003185A1
CL2012003185A1 CL2012003185A CL2012003185A CL2012003185A1 CL 2012003185 A1 CL2012003185 A1 CL 2012003185A1 CL 2012003185 A CL2012003185 A CL 2012003185A CL 2012003185 A CL2012003185 A CL 2012003185A CL 2012003185 A1 CL2012003185 A1 CL 2012003185A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
phase containing
hmg
tablets
preparation
Prior art date
Application number
CL2012003185A
Other languages
English (en)
Inventor
Yong Ii Kim
Young Jun Na
Min Jung Kim
Young-Hun Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45395310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of CL2012003185A1 publication Critical patent/CL2012003185A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steering Devices For Bicycles And Motorcycles (AREA)

Abstract

Formulación farmacéutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de HMG-COA reductasa y un aditivo alcalino; método de preparación de la formulación farmacéutica.
CL2012003185A 2010-05-14 2012-11-14 Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica. CL2012003185A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100045636 2010-05-14
KR1020100053782A KR101248804B1 (ko) 2010-05-14 2010-06-08 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Publications (1)

Publication Number Publication Date
CL2012003185A1 true CL2012003185A1 (es) 2013-02-22

Family

ID=45395310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003185A CL2012003185A1 (es) 2010-05-14 2012-11-14 Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica.

Country Status (36)

Country Link
US (1) US20130028974A1 (es)
EP (1) EP2568972B1 (es)
JP (1) JP5969466B2 (es)
KR (2) KR101248804B1 (es)
CN (1) CN103002883B (es)
AR (1) AR081032A1 (es)
AU (2) AU2011251085A1 (es)
BR (1) BR112012029064B8 (es)
CA (1) CA2798363C (es)
CL (1) CL2012003185A1 (es)
CO (1) CO6592025A2 (es)
CR (1) CR20120545A (es)
DK (1) DK2568972T3 (es)
DO (1) DOP2012000264A (es)
EA (1) EA023959B1 (es)
EC (1) ECSP12012224A (es)
ES (1) ES2645726T3 (es)
GT (1) GT201200309A (es)
HU (1) HUE036638T2 (es)
IL (1) IL223012B (es)
JO (1) JO3409B1 (es)
MA (1) MA34313B1 (es)
MX (1) MX342868B (es)
MY (1) MY157307A (es)
NI (1) NI201200170A (es)
NZ (1) NZ604402A (es)
PE (2) PE20130204A1 (es)
PH (1) PH12012501965A1 (es)
PL (1) PL2568972T3 (es)
PT (1) PT2568972T (es)
SG (1) SG185778A1 (es)
SI (1) SI2568972T1 (es)
TW (1) TW201200166A (es)
UA (1) UA107967C2 (es)
WO (1) WO2011142621A2 (es)
ZA (1) ZA201209481B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2014142607A1 (ko) * 2013-03-14 2014-09-18 보령제약 주식회사 약제학적 복합제제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN105769793A (zh) * 2016-04-04 2016-07-20 孙爱华 一种辛伐他汀片剂及其制备方法
CN113260355A (zh) * 2018-12-31 2021-08-13 保宁制药株式会社 片剂及其制备方法
KR102042626B1 (ko) * 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR102595702B1 (ko) * 2021-06-09 2023-10-30 주식회사 보령 약학적 복합 제제 및 제조 방법
WO2023152674A1 (en) * 2022-02-09 2023-08-17 Berlia Sushma Paul A pharmaceutical combination of antispasmodic and anxiolytic agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003073270A (ja) * 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
EP1467712B2 (en) * 2002-01-16 2011-08-31 Boehringer Ingelheim Pharma GmbH & Co. KG Method of producing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
WO2003105809A1 (en) * 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
AU2006212609A1 (en) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
CA2664893C (en) * 2006-10-30 2015-01-27 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
KR20090114333A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CN101590231A (zh) * 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem

Also Published As

Publication number Publication date
JP2013526516A (ja) 2013-06-24
BR112012029064A2 (pt) 2016-08-09
EP2568972B1 (en) 2017-08-02
IL223012A0 (en) 2013-02-03
CR20120545A (es) 2012-12-06
MY157307A (en) 2016-05-31
JP5969466B2 (ja) 2016-08-17
KR20110126020A (ko) 2011-11-22
IL223012B (en) 2019-03-31
KR101248804B1 (ko) 2013-03-29
UA107967C2 (en) 2015-03-10
BR112012029064B8 (pt) 2020-08-11
NZ604402A (en) 2015-02-27
TW201200166A (en) 2012-01-01
AU2011251085A1 (en) 2013-01-10
GT201200309A (es) 2014-03-14
MX2012013175A (es) 2013-01-17
DOP2012000264A (es) 2012-11-30
PT2568972T (pt) 2017-10-09
HK1181685A1 (zh) 2013-11-15
CN103002883A (zh) 2013-03-27
PL2568972T3 (pl) 2017-12-29
MA34313B1 (fr) 2013-06-01
ECSP12012224A (es) 2012-11-30
EA023959B1 (ru) 2016-07-29
JO3409B1 (ar) 2019-10-20
CN103002883B (zh) 2015-08-26
AU2016203739B2 (en) 2017-11-02
DK2568972T3 (da) 2017-11-06
EP2568972A2 (en) 2013-03-20
WO2011142621A2 (en) 2011-11-17
AR081032A1 (es) 2012-05-30
PH12012501965A1 (en) 2022-10-05
ZA201209481B (en) 2014-02-26
KR20130024940A (ko) 2013-03-08
MX342868B (es) 2016-10-17
PE20130204A1 (es) 2013-03-11
ES2645726T3 (es) 2017-12-07
CO6592025A2 (es) 2013-01-02
SG185778A1 (en) 2013-01-30
HUE036638T2 (hu) 2018-07-30
AU2016203739A1 (en) 2016-06-23
NI201200170A (es) 2013-05-29
CA2798363A1 (en) 2011-11-17
CA2798363C (en) 2018-06-05
BR112012029064B1 (pt) 2019-10-22
US20130028974A1 (en) 2013-01-31
WO2011142621A3 (en) 2012-03-08
EA201291247A1 (ru) 2013-04-30
SI2568972T1 (sl) 2017-10-30
EP2568972A4 (en) 2014-07-02
PE20151905A1 (es) 2016-01-07

Similar Documents

Publication Publication Date Title
CL2012003185A1 (es) Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica.
CY2019025I2 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
WO2012084126A3 (en) Formulation of lacosamide
CR20140332A (es) Inhibidores de bromodominios
WO2012015973A3 (en) Dynamic care areas
EP2776038A4 (en) ACC-HEMMER AND USES THEREOF
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
EP2636736A4 (en) NOVEL ANTI-DR5 ANTIBODY
EP2776837A4 (en) COMBINATION OF KINASEINHIBITORS AND THEIR USE
EP2654422A4 (en) BICYCLO [3.2.1] OCTYLAMID DERIVATIVES AND THEIR USE
CL2013001670A1 (es) Combinación farmacéutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos bortezomib; articulo de fabricación que comprende un material de envasado y la combinación antes dicha.
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
IL225434A0 (en) Pharmaceutical compositions containing a dgat1 inhibitor
NZ605060A (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
WO2011083114A3 (en) Serine hydrolase formulation
CL2015000363A1 (es) Una formulacion de una capsula farmaceutica compuesta que comprende 1) una unidad independiente comprendiendo irbesartan o una de sus sales y 2) una unidad independiente comprendiendo un inhibidor de la hmg-coa reductasa o una de sus sales y un aditivo alcalino, en donde dichas unidades independientes se separan unas de otras dentro de la capsula; y su metodo de preparacion.
EP2651401A4 (en) PHARMACEUTICAL COMPOSITION FORMULATION WITH AN HMG-COA REDUCTASE INHIBITOR AND ASPIRIN
ITTO20111220A1 (it) Composizione contenente un fosfato di tocoferolo e procedimento di preparazione.
CU20130016A7 (es) Composición farmacéutica de liberación prolongada de trimetazidina
WO2011096665A3 (en) Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
EP3090744A4 (en) Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor
WO2012127495A3 (en) Pharmaceutical composition and process for preparation thereof
CL2015000402A1 (es) Formulación de comprimidos compuestos de dos fases que comprende irbesartan, atorvastatina y carbonato de magnesio; metodo de preparacion.